MEPSGEN showcases ProMEPS™ at BIO KOREA 2024

- Will demonstrate the world's firstautomated microphysiological modeling system ’ProMEPS™’, and an automated scalablenanoparticle synthesis system ‘NanoCalibur™’

[Photo.ProMEPS™]

[Seoul/May 2, 2024] MEPSGEN,today announced that it will be exhibiting at BIO KOREA 2024, taking place fromMay 8 to 10 at COEX in Seoul, South Korea.

MEPSGEN is a biotechnology company thatdevelops human microphysiological system (MPS) for advanced prediction of drugtoxicity and efficacy and that engineers microvortex system for uniform andscalable nanoparticle synthesis from lab-scale discovery to GMP manufacturing.

At the event, MEPSGEN will be showcasingProMEPS™, the world’s first automated MPSmodeling system for all-in-one processing of MPSmodeling, developed and launched in November last year, for the first time inpublic. ProMEPS™ conducts all the modeling processes from cell injection to uniformmedium perfusion while monitoring the model integrity in real time. Thisinnovative system enables efficient development and mass production ofhigh-quality organ models with high reproducibility, while minimizing the timerequired for cell culture operations and precluding frequent manual variationsfor laborious protocol steps.

MEPSGEN plans to introduce a new 'OrganoidChip' designed to accommodate 32 organoids (0.2~3mm) and be applied to ProMEPS™for long-term stable production of organoids, addressing the current challengesof organoid manufacturing.

MEPSGEN will alsopreview NanoCalibur™, a scalable nanoparticle synthesissystem with high-precision feedback control of precursor flows to produceuniform LNPs carrying mRNA with high encapsulation efficiency, uniformity, andscalability. Last December, MEPSGEN was granted a patent for a microfluidic chipcapable of mass-producing nanoparticles, and in January, MEPSGEN applied for a patent for a unique method of preparing mRNA-LNPsfor vaccines. By leveraging these technologies, MEPSGEN plans to launch NanoCalibur™for laboratory use in June 2024, followed byNanoCalibur™ GMP in August 2024.

“The mass production of MPS with highreproducibility through ProMEPS™ will contribute to the increased reliabilityof preclinical experimental results in areas that are difficult to verify throughpreclinical animal experiments, accelerate standardization in the field ofalternatives to animal testing, and increase the success rate of new drugs inclinical trials, ultimately leading to a paradigm shift in drug development,” saidDr. YongTae Kim, CEO of MEPSGEN. “And we expect NanoCalibur™ to be a key manufacturing partner in the mRNA therapeutics market, whichis expanding beyond vaccines into new therapeutics such as cancer drugs andmore.”